204 related articles for article (PubMed ID: 26895086)
1. Retinoid-related orphan receptor gamma t (RORγt) inhibitors from Vitae Pharmaceuticals (WO2015116904) and structure proposal for their Phase I candidate VTP-43742.
Gege C
Expert Opin Ther Pat; 2016 Jun; 26(6):737-44. PubMed ID: 26895086
[TBL] [Abstract][Full Text] [Related]
2. RORγt inhibitors as potential back-ups for the phase II candidate VTP-43742 from Vitae Pharmaceuticals: patent evaluation of WO2016061160 and US20160122345.
Gege C
Expert Opin Ther Pat; 2017 Jan; 27(1):1-8. PubMed ID: 27852111
[TBL] [Abstract][Full Text] [Related]
3. Retinoid-related orphan receptor γ t modulators: comparison of Glenmark's me-too patent application (WO2015008234) with the originator application from Merck Sharp and Dohme (WO2012106995).
Gege C
Expert Opin Ther Pat; 2015; 25(10):1215-21. PubMed ID: 26156084
[TBL] [Abstract][Full Text] [Related]
4. Identification of the first inverse agonist of retinoid-related orphan receptor (ROR) with dual selectivity for RORβ and RORγt.
Gege C; Schlüter T; Hoffmann T
Bioorg Med Chem Lett; 2014 Nov; 24(22):5265-7. PubMed ID: 25305688
[TBL] [Abstract][Full Text] [Related]
5. Identification and structure activity relationships of quinoline tertiary alcohol modulators of RORγt.
Kummer DA; Cummings MD; Abad M; Barbay J; Castro G; Wolin R; Kreutter KD; Maharoof U; Milligan C; Nishimura R; Pierce J; Schalk-Hihi C; Spurlino J; Urbanski M; Venkatesan H; Wang A; Woods C; Xue X; Edwards JP; Fourie AM; Leonard K
Bioorg Med Chem Lett; 2017 May; 27(9):2047-2057. PubMed ID: 28318945
[TBL] [Abstract][Full Text] [Related]
6. Retinoic acid receptor-related orphan receptor gamma-t (RORγt) inhibitors in clinical development for the treatment of autoimmune diseases: a patent review (2016-present).
Sun N; Guo H; Wang Y
Expert Opin Ther Pat; 2019 Sep; 29(9):663-674. PubMed ID: 31403347
[No Abstract] [Full Text] [Related]
7. Combating Autoimmune Diseases With Retinoic Acid Receptor-Related Orphan Receptor-γ (RORγ or RORc) Inhibitors: Hits and Misses.
Pandya VB; Kumar S; Sachchidanand ; Sharma R; Desai RC
J Med Chem; 2018 Dec; 61(24):10976-10995. PubMed ID: 30010338
[TBL] [Abstract][Full Text] [Related]
8. RORγ antagonists and inverse agonists: a patent review.
Bronner SM; Zbieg JR; Crawford JJ
Expert Opin Ther Pat; 2017 Jan; 27(1):101-112. PubMed ID: 27629281
[TBL] [Abstract][Full Text] [Related]
9. Optimization and biological evaluation of thiazole-bis-amide inverse agonists of RORγt.
Gege C; Albers M; Kinzel O; Kleymann G; Schlüter T; Steeneck C; Hoffmann T; Xue X; Cummings MD; Spurlino J; Milligan C; Fourie AM; Edwards JP; Leonard K; Coe K; Scott B; Pippel D; Goldberg SD
Bioorg Med Chem Lett; 2020 Jun; 30(12):127205. PubMed ID: 32336498
[TBL] [Abstract][Full Text] [Related]
10. Structural studies unravel the active conformation of apo RORγt nuclear receptor and a common inverse agonism of two diverse classes of RORγt inhibitors.
Li X; Anderson M; Collin D; Muegge I; Wan J; Brennan D; Kugler S; Terenzio D; Kennedy C; Lin S; Labadia ME; Cook B; Hughes R; Farrow NA
J Biol Chem; 2017 Jul; 292(28):11618-11630. PubMed ID: 28546429
[TBL] [Abstract][Full Text] [Related]
11. Discovery of 3-Cyano- N-(3-(1-isobutyrylpiperidin-4-yl)-1-methyl-4-(trifluoromethyl)-1 H-pyrrolo[2,3- b]pyridin-5-yl)benzamide: A Potent, Selective, and Orally Bioavailable Retinoic Acid Receptor-Related Orphan Receptor C2 Inverse Agonist.
Schnute ME; Wennerstål M; Alley J; Bengtsson M; Blinn JR; Bolten CW; Braden T; Bonn T; Carlsson B; Caspers N; Chen M; Choi C; Collis LP; Crouse K; Färnegårdh M; Fennell KF; Fish S; Flick AC; Goos-Nilsson A; Gullberg H; Harris PK; Heasley SE; Hegen M; Hromockyj AE; Hu X; Husman B; Janosik T; Jones P; Kaila N; Kallin E; Kauppi B; Kiefer JR; Knafels J; Koehler K; Kruger L; Kurumbail RG; Kyne RE; Li W; Löfstedt J; Long SA; Menard CA; Mente S; Messing D; Meyers MJ; Napierata L; Nöteberg D; Nuhant P; Pelc MJ; Prinsen MJ; Rhönnstad P; Backström-Rydin E; Sandberg J; Sandström M; Shah F; Sjöberg M; Sundell A; Taylor AP; Thorarensen A; Trujillo JI; Trzupek JD; Unwalla R; Vajdos FF; Weinberg RA; Wood DC; Xing L; Zamaratski E; Zapf CW; Zhao Y; Wilhelmsson A; Berstein G
J Med Chem; 2018 Dec; 61(23):10415-10439. PubMed ID: 30130103
[TBL] [Abstract][Full Text] [Related]
12. Identification of Tetraazacyclic Compounds as Novel Potent Inhibitors Antagonizing RORγt Activity and Suppressing Th17 Cell Differentiation.
Ding Q; Zhao M; Yu B; Bai C; Huang Z
PLoS One; 2015; 10(9):e0137711. PubMed ID: 26368822
[TBL] [Abstract][Full Text] [Related]
13. Design, Synthesis, and Biological Evaluation of Retinoic Acid-Related Orphan Receptor γt (RORγt) Agonist Structure-Based Functionality Switching Approach from In House RORγt Inverse Agonist to RORγt Agonist.
Yukawa T; Nara Y; Kono M; Sato A; Oda T; Takagi T; Sato T; Banno Y; Taya N; Imada T; Shiokawa Z; Negoro N; Kawamoto T; Koyama R; Uchiyama N; Skene R; Hoffman I; Chen CH; Sang B; Snell G; Katsuyama R; Yamamoto S; Shirai J
J Med Chem; 2019 Feb; 62(3):1167-1179. PubMed ID: 30652849
[TBL] [Abstract][Full Text] [Related]
14. Structural States of RORγt: X-ray Elucidation of Molecular Mechanisms and Binding Interactions for Natural and Synthetic Compounds.
Kallen J; Izaac A; Be C; Arista L; Orain D; Kaupmann K; Guntermann C; Hoegenauer K; Hintermann S
ChemMedChem; 2017 Jul; 12(13):1014-1021. PubMed ID: 28590087
[TBL] [Abstract][Full Text] [Related]
15. Transcription Factor Retinoid-Related Orphan Receptor γt: A Promising Target for the Treatment of Psoriasis.
Tang L; Yang X; Liang Y; Xie H; Dai Z; Zheng G
Front Immunol; 2018; 9():1210. PubMed ID: 29899748
[TBL] [Abstract][Full Text] [Related]
16. Discovery of N-(2-benzyl-4-oxochroman-7-yl)-2-(5-(ethylsulfonyl) pyridin-2-yl) acetamide (b12) as a potent, selective, and orally available novel retinoic acid receptor-related orphan receptor γt inverse agonist.
Chen L; Su M; Jin Q; Wang CG; Assani I; Wang MX; Zhao SF; Lv SM; Wang JW; Sun B; Li Y; Liao ZX
Bioorg Chem; 2022 Feb; 119():105483. PubMed ID: 34906860
[TBL] [Abstract][Full Text] [Related]
17. Identification of potent, selective and orally bioavailable phenyl ((R)-3-phenylpyrrolidin-3-yl)sulfone analogues as RORγt inverse agonists.
Lu Z; Duan JJ; Xiao H; Neels J; Wu DR; Weigelt CA; Sack JS; Khan J; Ruzanov M; An Y; Yarde M; Karmakar A; Vishwakrishnan S; Baratam V; Shankarappa H; Vanteru S; Babu V; Basha M; Kumar Gupta A; Kumaravel S; Mathur A; Zhao Q; Salter-Cid LM; Carter PH; Murali Dhar TG
Bioorg Med Chem Lett; 2019 Aug; 29(16):2265-2269. PubMed ID: 31257087
[TBL] [Abstract][Full Text] [Related]
18. (Inverse) Agonists of Retinoic Acid-Related Orphan Receptor γ: Regulation of Immune Responses, Inflammation, and Autoimmune Disease.
Jetten AM; Cook DN
Annu Rev Pharmacol Toxicol; 2020 Jan; 60():371-390. PubMed ID: 31386594
[TBL] [Abstract][Full Text] [Related]
19. Discovery of a potent orally bioavailable retinoic acid receptor-related orphan receptor-gamma-t (RORγt) inhibitor, S18-000003.
Sasaki Y; Odan M; Yamamoto S; Kida S; Ueyama A; Shimizu M; Haruna T; Watanabe A; Okuno T
Bioorg Med Chem Lett; 2018 Dec; 28(22):3549-3553. PubMed ID: 30301676
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and Biological Evaluation of New Triazolo- and Imidazolopyridine RORγt Inverse Agonists.
Hintermann S; Guntermann C; Mattes H; Carcache DA; Wagner J; Vulpetti A; Billich A; Dawson J; Kaupmann K; Kallen J; Stringer R; Orain D
ChemMedChem; 2016 Dec; 11(24):2640-2648. PubMed ID: 27902884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
